Fortitude Family Office’s Amphastar Pharmaceuticals AMPH Stock Holding History

Fortitude Family Office’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.9K	Buy	+462	New	+$9.99K	﹤0.01%	1133

Other funds holding AMPH

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return

GWM

Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

DCM

Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Fortitude Family Office's AMPH Position: Q3 2026 in Review

Fortitude Family Office opened a new position in Amphastar Pharmaceuticals (AMPH) in Q3 2026: 462 shares worth $11.9K. The stake represents ﹤0.01% of the portfolio and ranks #1133 among its holdings.

11 funds tracked by Wall St. Rank hold AMPH as of Q3 2026.

Fortitude Family Office held 462 shares of Amphastar Pharmaceuticals worth $11.9K as of Q3 2026.
Amphastar Pharmaceuticals was a new Fortitude Family Office position in Q3 2026.
Amphastar Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1133 holding.
11 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.